# Vitruvias Therapeutics, Inc.

> Vitruvias Therapeutics was a finished-dose generic drug developer built in Auburn, Alabama in 2013 by a team that had already built and sold two pharmaceutical companies. Instead of pouring capital into plants, Vitruvias picked technically difficult generics - including hard-to-copy sterile injectables and extended-release capsules - and licensed development, manufacturing and distribution through domestic and international partners. It raised an $11.5 million Series A in 2018, landed its first FDA approval in 2017, and its products are now owned and distributed by H2-Pharma.

- **Founded:** 2013
- **Headquarters:** Auburn, Alabama, United States
- **Founders:** Carl L. Whatley (Chairman, CEO & Co-Founder), Bryce Harvey (Co-Founder & Executive Vice President)
- **Team size:** ~6 employees
- **Products:** Generic drug development (ANDA portfolio), First ANDA approval, Potassium Chloride ER Capsules (10 and 20 mEq)
- **Notable:** Received first FDA ANDA approval in September 2017., Closed an $11.5 million Series A in January 2018 led by JW Asset Management and Perceptive Advisors., Founding team previously built and sold ProEthic Pharmaceuticals (acquired by Kowa Company) and Midlothian Laboratories (acquired by Mayne Pharma).

## Products & services

- **Generic drug development (ANDA portfolio)** — Development and commercialization of finished-dose generic drugs, with a focus on technically difficult products including sterile injectables.
- **First ANDA approval** — Received its first FDA Abbreviated New Drug Application approval, with commercial launch planned for early 2018.
- **Potassium Chloride ER Capsules (10 and 20 mEq)** — Licensed extended-release potassium chloride capsules - used to treat hypokalemia (low blood potassium) - manufactured under contract at Bora Pharmaceutical's Zhunan facility in Taiwan.

## Achievements

- Received first FDA ANDA approval in September 2017.
- Closed an $11.5 million Series A in January 2018 led by JW Asset Management and Perceptive Advisors.
- Founding team previously built and sold ProEthic Pharmaceuticals (acquired by Kowa Company) and Midlothian Laboratories (acquired by Mayne Pharma).
- Signed a cross-border contract manufacturing deal with Bora Pharmaceuticals in Taiwan for potassium chloride ER capsules.
- Built and exited a functioning generics portfolio now carried by H2-Pharma.

## Latest updates

- **2018-01** — Completed $11.5M Series A preferred financing led by JW Asset Management and Perceptive Advisors; Jason Wild, Michael Altman and Arbor Pharmaceuticals CEO Ed Schutter joined the board.
- **2018-12** — Licensed Potassium Chloride ER (10 and 20 mEq) capsules to be manufactured at Bora Pharmaceutical's new Zhunan facility in Taiwan.
- **2024-01** — Company operations wound down; products now owned and/or distributed by H2-Pharma LLC of Montgomery, Alabama.

## Links

- Website: https://vitruvias.com
- LinkedIn: http://www.linkedin.com/company/vitruvias-therapeutics-llc

---

Profile page: https://yespress.io/vitruvias-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-20